Skip to main content

Table 1 Acalabrutinib (ACP-196) for hematological malignancies

From: Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Agents

Diseases

Phase

NCT

ACP-196

Dexamethasone

MM

Phase 1

NCT02211014

ACP-196

ABC DLBCL

Phase 1

NCT02112526

ACP-196

Rituximab (IV)

FL

Phase 1

NCT02180711

ACP-196

Obinutuzumab

CLL, SLL, PLL

Phase 1

NCT02296918

ACP-196

ACP-319

CLL

Phase 1

NCT02157324

ACP-196

ACP-319

NHL, MM, B-All

Phase 1/2

NCT02328014

ACP-196

WM

Phase 1/2

NCT02180724

ACP-196

CLL, SLL, RS, PLL

Phase 1/2

NCT02029443

ACP-196

Pembrolizumab

NHL, MM, HL, CLL, RS, WM, Myelofibrosis

Phase 1/2

NCT02362035

ACP-196

CLL, SLL

Phase 2

NCT02337829

ACP-196

MCL

Phase 2

NCT02213926

ACP-196

Obinutuzumab

Chlorambucil

CLL

Phase 3

NCT02475681

ACP-196

Ibrutinib

CLL

Phase 3

NCT02477696

  1. NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM multiple myeloma, MCL mantle cell lymphoma, FL follicular lymphoma, ABC DLBCL activated B cell diffuse large B cell lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocytic lymphoma, WM Waldenstrom’s macroglobulinemia, RS Richter’s syndrome, PLL prolymphocytic leukemia